These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 15523367

  • 1. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH.
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ, Wolverton SE.
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH, Prose NS, Ware RE, Hall RP.
    Pediatr Dermatol; 2005 Sep; 22(5):461-4. PubMed ID: 16191003
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ, Engert A, Krieg T, Hunzelmann N.
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [Abstract] [Full Text] [Related]

  • 5. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK, Posner MR, Spigelman Z, Ahmed AR.
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in refractory pemphigus vulgaris.
    Sorce M, Aricò M, Bongiorno MR.
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [Abstract] [Full Text] [Related]

  • 7. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
    Dupuy A, Viguier M, Bédane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H.
    Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
    [Abstract] [Full Text] [Related]

  • 8. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A, Gniadecki R.
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [Abstract] [Full Text] [Related]

  • 9. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
    Barrera MV, Mendiola MV, Bosch RJ, Herrera E.
    J Dermatolog Treat; 2007 Mar; 18(5):312-4. PubMed ID: 17852643
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.
    N Engl J Med; 2006 Oct 26; 355(17):1772-9. PubMed ID: 17065638
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in severe pemphigus.
    Schmidt E, Goebeler M, Zillikens D.
    Ann N Y Acad Sci; 2009 Sep 26; 1173():683-91. PubMed ID: 19758216
    [Abstract] [Full Text] [Related]

  • 13. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr 26; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 14. Delayed response of oral pemphigus vulgaris to rituximab treatment.
    Niedermeier A, Wörl P, Barth S, Schuler G, Hertl M.
    Eur J Dermatol; 2006 Apr 26; 16(3):266-70. PubMed ID: 16709491
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.
    Rheumatology (Oxford); 2006 Nov 26; 45(11):1432-6. PubMed ID: 16632482
    [Abstract] [Full Text] [Related]

  • 17. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P.
    Arch Dermatol; 2007 Aug 26; 143(8):1033-8. PubMed ID: 17709662
    [Abstract] [Full Text] [Related]

  • 18. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
    Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM.
    Br J Dermatol; 2007 May 26; 156(5):990-6. PubMed ID: 17355229
    [Abstract] [Full Text] [Related]

  • 19. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
    Antonucci A, Negosanti M, Tabanelli M, Varotti C.
    J Dermatolog Treat; 2007 May 26; 18(3):178-83. PubMed ID: 17538808
    [Abstract] [Full Text] [Related]

  • 20. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.
    Ann Rheum Dis; 2008 Dec 26; 67(12):1724-31. PubMed ID: 18250115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.